Link Biologics strengthens Board with drug discovery expert Dr Niall Martin to advance its TSG-6-based therapeutic pipeline
Dr Martin brings over two decades of leadership in translational science, drug discovery and biotech strategy and entrepreneurship Strengthens Link’s position as it advances its proprietary TSG-6-based therapeutic pipeline towards the clinic London, UK – 24 February 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies, that have a unique […]
